Santen Financial Statements From 2010 to 2024
| SNPHF Stock | USD 10.53 0.62 5.56% |
Check Santen Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Santen Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Santen financial statements analysis is a perfect complement when working with Santen Pharmaceutical Valuation or Volatility modules.
Santen |
Santen Pharmaceutical Co Company Return On Equity Analysis
Santen Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Santen Pharmaceutical Return On Equity | -0.0264 |
Most of Santen Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Santen Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Santen Pharmaceutical Co has a Return On Equity of -0.0264. This is 99.89% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—General industry. The return on equity for all United States stocks is 91.48% lower than that of the firm.
Santen Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Santen Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Santen Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Santen Pharmaceutical competition to find correlations between indicators driving Santen Pharmaceutical's intrinsic value. More Info.Santen Pharmaceutical Co is currently regarded as top stock in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Santen Pharmaceutical's earnings, one of the primary drivers of an investment's value.About Santen Pharmaceutical Financial Statements
Santen Pharmaceutical stakeholders use historical fundamental indicators, such as Santen Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Santen Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Santen Pharmaceutical's assets and liabilities are reflected in the revenues and expenses on Santen Pharmaceutical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Santen Pharmaceutical Co. Please read more on our technical analysis and fundamental analysis pages.
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Santen Pink Sheet
Santen Pharmaceutical financial ratios help investors to determine whether Santen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santen with respect to the benefits of owning Santen Pharmaceutical security.